ABOVE: © ISTOCK.COM, MONGKOLCHON AKESIN
Update (March 23): The US National Institutes of Allergy and Infectious Diseases’s Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” NIAID said in a statement today. AstraZeneca responded in its own statement that the data came from a prespecified interim analysis and that the company “will immediately engage with the independent data safety monitoring board (DSMB) to share our primary analysis with the most up to date efficacy data.”
No recipients of Oxford/AstraZeneca’s COVID-19 vaccine developed serious symptoms or went to the hospital because of a SARS-CoV-2 infection, indicating the immunization may completely protect against severe disease, according to data from a Phase 3 trial conducted in the US, Chile, and Peru. The two-dose immunization was also 79 percent effective at preventing symptomatic cases, the company ...
